Clinicopathologic Characteristics, Progression, and Prognostic Analysis of IPNB

The main aim of this observational study is to understand the clinicopathological and prognostic information of IPNB, a rare tumor. The participants have already received treatment during their previous routine medical management and took part in follow - up. We will look into their survival information after previous medical visits and treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bile Duct Neoplasms Malignant Disease Attributes Disease Progression Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

the First Hospital of Jilin University

Changchun, Jililn, 130000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

IPNB with or without malignant transformation was confirmed by pathological examination

Exclusion criteria

missing other essential clinical data
coexisting malignant tumors of other digestive system organs

Treatment and study plan

Primary outcomes

death

Time frame: From January 2014 to June 2024

Died of various causes after treatment

Sponsors and collaborators

Lead sponsor

The First Hospital of Jilin University

Other

Registry information

Official study title

Clinicopathologic Characteristics, Progression, and Prognostic Analysis of Intraductal Papillary Neoplasm of Bile Duct

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Mar 20, 2025
Registry last updated: Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed